drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.
|Published (Last):||10 November 2010|
|PDF File Size:||18.8 Mb|
|ePub File Size:||8.33 Mb|
|Price:||Free* [*Free Regsitration Required]|
Please review the latest applicable package insert for additional information and possible updates. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Administering inducers of hepatic cytochrome P, such as phenytoin, concurrently with caspofungin may reduce the plasma concentrations of caspofungin.
Oral antifungal agents e. Related Drug Information Drug Summary. Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The mechanism of this interaction has not been identified; monitor tacrolimus blood concentrations.
Standardized susceptibility cancidax using microbroth dilution methods read at 24 hours are available for Candida sp. Send the page ” ” to a friend, relative, colleague or yourself. Intermittent and Continuous Hemodialysis Caspofungin is not dialyzable.
Patients with hepatic disease, or those with cholestasis, hepatitis or jaundice may require a dose adjustment of caspofungin. Treat suppurative thrombophlebitis for at least 2 weeks after candidemia if present has cleared. Chemical degradation leads to the formation of the metabolite L and very low levels of reactive intermediates.
There is no clinical experience in those with severe hepatic impairment Child-Pugh score more than 9, class C. In murine models, caspofungin has been shown to have less activity against histoplasmosis than amphotericin B. Esophageal Candidiasis The dose should be 50 mg daily. The final diluted infusion may be nisert for up to 24 hours at 25 degrees C or less 77 degrees F or lessor for up to 48 hours under refrigeration at 2 to 8 degrees C.
The safety and efficacy of doses above 70 mg have not been adequately studied. Caspofungin inhibits the synthesis of a major fungal cell wall component, beta 1,3 -D-glucan.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi
Do not administer as an IV bolus injection. Very limited data are available. Caspofungin is contraindicated in patients with known hypersensitivity to any component of this product. Important Safety Information Caspofungin is contraindicated in patients with known hypersensitivity to any component of this product.
Treatment for at least 14 days and for at cancidass 7 days after neutropenia and symptoms resolve is recommended for patients found to have a fungal infection. Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: Although an increase in efficacy with 70 mg daily has not been demonstrated, limited safety data suggest that an increase in dose to 70 mg daily is well tolerated.
Morphologically, fungi hyphae and yeast shapes are altered. A short alpha-phase is followed by a beta-phase half-life of 9—11 hours ; once daily dosing is adequate. Do not store for later use. The pharmacokinetic parameters of caspofungin are not altered by tacrolimus. Restrict treatment to pneumonia associated with disseminated infection. Do not use any diluents containing dextrose to prepare caspofungin.
Dosage and administration 2. For empirical therapy for presumed fungal infection in patients with febrile isert. It is not known how caspofungin drug clearance is induced.
Cancidas (caspofungin acetate) dose, indications, adverse effects, interactions from
Coadministration of caspofungin with CYP enzyme inducers, such as the rifamycins, results in reduced caspofungin blood concentrations. No data are available on the use of caspofungin in patients with severe hepatic disease i.
Successful treatment of invasive candidiasis has been reported in neonates and young infants; however, available data are limited to small case series and studies. Measure potassium concentrations at baseline and periodically during dichlorphenamide treatment. Although specific neonatal recommendations are not available, clinical practice guidelines suggest caspofungin as salvage therapy. For the treatment of intraabdominal packate in patients who are refractory to or intolerant of other antifungal therapies.
No adjustment in the loading dose is needed. Remove peritoneal dialysis catheter. Supplemental dosing is not required following hemodialysis. According to the manufacturer, drugs that pacckage lead to reductions in pakcage concentrations include carbamazepine.
For the insertt of intraabdominal candidiasis. Cyclosporine concentrations are not altered by coadministration with caspofungin. Monitor potentially exposed infants for gastrointestinal adverse events and signs of histamine release.